Abstract
Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and thirdgeneration calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable “therapeutic cross effects” due to pleiotropic mechanisms can be defined as pleiosynergy.
Keywords: Statin, amlodipine, vascular effect, pleiotropic, synergy
Current Vascular Pharmacology
Title: Vascular Pleiosynergy - Does It Really Work?
Volume: 5 Issue: 4
Author(s): Albert Csaszar
Affiliation:
Keywords: Statin, amlodipine, vascular effect, pleiotropic, synergy
Abstract: Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and thirdgeneration calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable “therapeutic cross effects” due to pleiotropic mechanisms can be defined as pleiosynergy.
Export Options
About this article
Cite this article as:
Csaszar Albert, Vascular Pleiosynergy - Does It Really Work?, Current Vascular Pharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157016107782023352
DOI https://dx.doi.org/10.2174/157016107782023352 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Isoindole Derivatives: Propitious Anticancer Structural Motifs
Current Topics in Medicinal Chemistry Analysis of Tocopherols and Tocotrienols in Pharmaceuticals and Foods: A Critical Review
Current Pharmaceutical Analysis The Cardiovascular and Cardiac Actions of Ecstasy and its Metabolites
Current Pharmaceutical Biotechnology Use of Metformin and Survival of Diabetic Women with Breast Cancer
Current Drug Safety Cardiac Repair: The Intricate Crosstalk between the Epicardium and the Myocardium
Current Stem Cell Research & Therapy Preliminary Structural Studies of the Hydrophobic Ribosomal P0 Protein from Trypanosoma cruzi, A Part of the P0/P1/P2 Complex
Protein & Peptide Letters Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Anti-Infective Agents The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Retraction Notice: Emerging Targets for COPD Therapy
Current Drug Targets - Inflammation & Allergy Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry A Role for Rev-erbα Ligands in the Regulation of Adipogenesis
Current Pharmaceutical Design Alternative Pharmacological Interventions that Limit Myocardial Infarction
Current Medicinal Chemistry Genetic Interactions Effects of Cardiovascular Disorder Using Computational Models: A Review
Current Biotechnology Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design The Role of Berberine in the Multi-Target Treatment of Senile Dementia
Current Topics in Medicinal Chemistry The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review
Current Cardiology Reviews